Chemosat®

Delcath®

Publications

1. Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study. https://link.springer.com/article/10.1245/s10434-024-15293-x
2. Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study. https://link.springer.com/article/10.1245/s10434-020-08741-x
3. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. https://link.springer.com/article/10.1007/s00270-019-02177-x
4. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. https://link.springer.com/article/10.1007/s00270-022-03338-1
5. Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic Uveal Melanoma. https://www.researchgate.net/publication/376260819_Quality_of_life_after_melphalan_percutaneous_hepatic_perfusion_for_patients_with_metastatic_Uveal_Melanoma
6. Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases. https://link.springer.com/article/10.1007/s00270-024-03713-0
7. Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study. https://www.mdpi.com/2072-6694/15/20/4942
8. Melanoma-specific survival of patients with uveal melanoma and liver metastases diagnosed between 2005 and 2021-Free Survival After Percutaneous Hepatic Perfusion (PHP) https://journals.sagepub.com/doi/full/10.1177/17588359241273020
9. Hepatic and Overall Progression as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma. https://link.springer.com/article/10.1245/s10434-024-16039-5
10. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis. https://link.springer.com/article/10.1007/s00270-022-03225-9

11. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver dominant metastatic uveal melanoma: a single center experience. https://cancerimagingjournal.biomedcentral.com/articles/10.1186/s40644-019-0218-4
12. Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden. https://onlinelibrary.wiley.com/doi/10.1155/2020/5672048
13. Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience. https://www.mdpi.com/2072-6694/14/1/118?type=check_update&version=2
14. Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. https://journals.lww.com/melanomaresearch/fulltext/2022/04000/chemosaturation_with_percutaneous_hepatic.5.aspx
15. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. https://link.springer.com/article/10.1007/s10585-020-10057-9
16. Peri-Interventional Hemodynamic Management Strategies for Percutaneous Chemosaturation of the Liver in Metastatic Cancer. https://www.mdpi.com/2072-6694/16/21/3698
17. Effects of Protamine Reversal on Coagulation Parameters After High-Dose Heparin Administration in Percutaneous Hepatic Chemosaturation Intervention. https://www.mdpi.com/2039-7283/15/2/38
18. Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation. https://www.esmogastro.org/article/S2949-8198(24)00043-8/fulltext
19. Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence https://www.cancertreatmentreviews.com/article/S0305-7372(22)00177-3/abstract
20. Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. https://link.springer.com/article/10.1007/s00270-021-02983-2

21. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma https://link.springer.com/article/10.1007/s00432-020-03289-5
22. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival https://link.springer.com/article/10.1007/s00330-018-5729-z